Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Ovarian Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma in Situ 1Carcinoma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

dodecyl maltoside 2Magnetic Resonance Imaging 2Electrocardiography 2Diphenhydramine 2Acetaminophen 2toripalimab 1fludarabine phosphate 1fludarabine 1enfortumab vedotin 1durvalumab 1cemiplimab 1aldesleukin 1Tomography, X-Ray Computed 1Sampling Studies 1Respiratory Function Tests 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Mitomycin 1Meperidine 1Mastectomy, Subcutaneous 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Hydroxyzine 1Histamine Antagonists 1Granisetron 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma in Situ × Indomethacin × 1 year × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡